MARKET

NUVL

NUVL

Nuvalent, Inc.
NASDAQ
102.32
+1.32
+1.31%
After Hours: 103.00 +0.68 +0.66% 19:19 05/20 EDT
OPEN
101.18
PREV CLOSE
101.00
HIGH
103.82
LOW
101.18
VOLUME
403.38K
TURNOVER
--
52 WEEK HIGH
113.02
52 WEEK LOW
70.25
MARKET CAP
8.08B
P/E (TTM)
-16.9040
1D
5D
1M
3M
1Y
5Y
1D
Assessing Nuvalent (NUVL) Valuation After Recent Share Price Volatility And DCF Upside Signals
Simply Wall St · 1d ago
Analyst Reiterates Buy on Nuvalent, Sees Best-in-Class Oncology Catalysts and Maintains $126 Price Target
TipRanks · 1d ago
Weekly Report: what happened at NUVL last week (0511-0515)?
Weekly Report · 2d ago
Analysts Offer Insights on Healthcare Companies: Adlai Nortye Ltd. Sponsored ADR (ANL), Protagonist Therapeutics (PTGX) and Nuvalent (NUVL)
TipRanks · 6d ago
Analysts Are Bullish on Top Healthcare Stocks: Molina Healthcare (MOH), Cencora (COR)
TipRanks · 05/11 10:30
Weekly Report: what happened at NUVL last week (0504-0508)?
Weekly Report · 05/11 09:16
Assessing Nuvalent (NUVL) Valuation After NDA Milestones Guardant Alliance And Quarterly Loss
Simply Wall St · 05/10 21:33
Nuvalent Maintained at Buy as Advancing Precision Oncology Pipeline Supports Unchanged $126 Price Target
TipRanks · 05/08 17:56
More
About NUVL
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.

Webull offers Nuvalent, Inc stock information, including NASDAQ: NUVL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NUVL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NUVL stock methods without spending real money on the virtual paper trading platform.